NEW YORK – Caris Life Sciences and Flatiron Health said on Monday that they have inked a deal to combine their databases of real-world multimodal data to advance oncology drug development.
For its part of the deal, Caris will bring its genomic, transcriptomic, proteomic, and imaging database, which includes more than 50 petabytes of oncology-specific data. Caris has whole-exome sequencing DNA coverage and whole-transcriptome sequencing RNA coverage for every patient tested with its technology.
Roche subsidiary Flatiron Health, meanwhile, will bring to the partnership its longitudinal patient data, including patients' clinical outcomes. Biopharmaceutical companies will then be able to tap into the combined database to inform personalized drug development.
"Identifying sufficient numbers of records to build cohorts of adequate size that can be used to address the most pressing research questions is a challenge that plagues the oncology community," Caris Chief Business Officer Brian Lamon said in a statement. "With Caris and Flatiron's combined strength and broad reach across oncology, we can provide this incredibly powerful data at a scale that will fuel drug discovery and therapeutic innovation."
The firms didn't provide further details or terms of their agreement.